Moreover, controlling glucose levels in diabetic mice with a sodium glucose co-transporter 2 inhibitor (SGLT2i) reduces circulating S100A8/A9 and prevents both diabetes-induced myelopoiesis and atherosclerosis. This evidence concerns the gene S100A8 and atherosclerosis.